83P The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies "pure" IRAEs strongly associated with outcome in a phase I-II trial population. (December 2022) - Mazzarella, L.; Nicolo, E.; Esposito, A.; Crimini, E.; Tini, G.; Uliano, J.; Corti, C.; Trillo Aliaga, P.M.; Valenza, C.; Repetto, M.; Antonarelli, G.; Minchella, I.; et al.